Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 13Unknown 4Terminated 3Withdrawn 1Recruiting 1Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Hypoxia 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Gastrointestinal Stromal Tumors 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × TH 302 × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02020226 2016-06-02

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Unknown
40 enrolled
Other solid neoplasm

Solid Tumors

NCT01381822 2014-04-21

TH-CR-410

Threshold Pharmaceuticals

Phase 1 Unknown
58 enrolled
GastrointestinalSarcoma

Neuroectodermal Tumors, Primitive, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡